The initiation of the Phase 1 clinical trial for CDX-585 is a positive development for Celldex Therapeutics, as it represents progress in their pipeline. This news could potentially attract investor interest and have a positive impact on the stock price in the short term. However, it is important to note that the trial is still in its early stages, and the outcome is uncertain.